Invivyd reported statistically significant Phase 3 safety and tolerability results for VYD2311 compared with an mRNA-based COVID-19 vaccine and said it plans to pursue an Accelerated Approval BLA pending supportive results from its ongoing DECLARATION study.
Key Investor Takeaways
- Invivyd (NASDAQ:IVVD) said VYD2311 showed significantly lower rates of short-term overall adverse events and systemic adverse events than the mRNA COVID-19 vaccine in the Phase 3 LIBERTY study.
- Over six days, 56.5% of VYD2311 recipients experienced a treatment-emergent adverse event, injection-site reaction or hypersensitivity reaction, compared with 91.4% for the vaccine group, with P<0.0001.
- Invivyd plans to pursue Accelerated Approval for VYD2311, subject to supportive placebo-controlled safety and neutralizing antibody data from the DECLARATION Phase 3 study.
- No VYD2311-related adverse events exceeded Grade 2, while no hypersensitivity or anaphylaxis was observed in any LIBERTY treatment arm.
- DECLARATION, which has approximately 2,400 participants, now represents the key upcoming clinical and regulatory catalyst for the VYD2311 program.
Why IVVD Stock Is in Focus
Invivyd’s Phase 3 LIBERTY study produced statistically significant results on both co-primary endpoints when VYD2311 was compared with an mRNA-based COVID-19 vaccine.
The randomized, double-blind study enrolled 210 healthy adults aged 18 to 49 and assigned them to a single 250 mg intramuscular dose of VYD2311, COMIRNATY or a combination of the two.
During the first six days, 56.5% of participants receiving VYD2311 experienced a treatment-emergent adverse event, injection-site reaction or hypersensitivity reaction, compared with 91.4% receiving the mRNA vaccine. The difference was statistically significant at P<0.0001.
For systemic adverse events recorded during the same period, the rates were 44.1% for VYD2311 and 68.1% for the vaccine, with P=0.008.
The difference persisted over longer follow-up. At 56 days, 60.9% of VYD2311 recipients experienced a treatment-emergent adverse event, injection-site reaction or hypersensitivity reaction compared with 91.4% of vaccine recipients, with P<0.0001.
Why This Matters for Investors
The LIBERTY results provide Invivyd with Phase 3 comparative safety and tolerability data as it prepares a potential regulatory submission for VYD2311.
The regulatory pathway is particularly relevant. Following discussions with the FDA, including a Type C meeting in September, Invivyd said it intends to submit a Biologics License Application under the Accelerated Approval Program if upcoming DECLARATION results are supportive.
LIBERTY also examined whether combining VYD2311 with an mRNA vaccine created immunologic interference. According to Invivyd, the combination increased neutralizing titers by approximately 2.5 times compared with the vaccine alone. After VYD2311 was removed from combination samples, vaccine-derived neutralizing titers were essentially identical to those in the vaccine-only arm, which the company said confirmed a lack of immunologic interference.
The combination results could provide another avenue for future research, but they are not the immediate regulatory focus. The central development remains whether DECLARATION produces data sufficient to support Invivyd’s planned Accelerated Approval submission.
Invivyd plans to unblind and report placebo-controlled safety and neutralizing antiviral titer data from DECLARATION while keeping accumulated clinical events blinded. If supportive, the company intends to use DECLARATION and LIBERTY alongside prior monoclonal antibody data in its Accelerated Approval application.
What to Watch Next
The upcoming DECLARATION data represent the most important next milestone. The Phase 3 trial is evaluating VYD2311 against placebo for prevention of symptomatic COVID-19 and has enrolled approximately 2,400 adults and adolescents.
Investors can watch for placebo-controlled safety and neutralizing antiviral titer results, followed by a potential BLA submission if those findings support the regulatory strategy.
Invivyd also plans to continue collecting blinded PCR-positive symptomatic COVID-19 events in a post-approval confirmatory randomized cohort if Accelerated Approval is obtained, targeting greater statistical power for evaluating efficacy.